Merck is the Big Pharma company producing an experimental antiviral pill for Covid-19 treatment is accused of selling the drug to the US at 40 times the cost of its production, found a report. Molnupiravir, manufactured by pharmaceutical company Merck, has entered into a contract with the US government to supply 1.7 million courses at a price of $700 per course.
Continue reading “Merck prices Molnupiravir at a 4000% mark up”
Michael Capuzzo, a New York Times best-selling author , has just published an article titled “The Drug That Cracked Covid”. The 15-page article chronicles the gargantuan struggle being waged by frontline doctors on all continents to get ivermectin approved as a Covid-19 treatment, as well as the tireless efforts by reporters, media outlets and social media companies to thwart them. Because of ivermectin, Capuzzo says, there are “hundreds of thousands, actually millions, of people around the world, from Uttar Pradesh in India to Peru to Brazil, who are living and not dying.” Yet media outlets have done all they can to “debunk” the notion that ivermectin may serve as an effective, easily accessible and affordable treatment for Covid-19. They have parroted the arguments laid out by health regulators around the world that there just isn’t enough evidence to justify its use. For his part, Capuzzo, as a reporter, “saw with [his] own eyes the other side [of the story]” that has gone unreported, of the many patients in the US whose lives have been saved by ivermectin and of five of the doctors that have led the battle to save lives around the world, Paul Marik, Umberto Meduri, José Iglesias, Pierre Kory and Joe Varon. These are all highly decorated doctors. Through their leadership of the Front Line COVID-19 Critical Care (FLCCC) Alliance, they have already enhanced our treatment of Covid-19 by discovering and promoting the use of Corticoid steroids against the virus. But their calls for ivermectin to also be used have met with a wall of resistance from healthcare regulators and a wall of silence from media outlets.
“I really wish the world could see both sides,” Capuzzo laments. But unfortunately most reporters are not interested in telling the other side of the story. Even if they were, their publishers would probably refuse to publish it.
That may explain why Capuzzo, a six-time Pulitzer-nominated journalist best known for his New York Times-bestselling nonfiction books Close to Shore and Murder Room, ended up publishing his article on ivermectin in Mountain Home, a monthly local magazine for the of the Pennsylvania mountains and New York Finger Lakes region, of which Capuzzo’s wife is the editor. It’s also the reason why I decided to dedicate today’s post to Capuzzo’s article. Put simply, as many people as possible –particularly journalists — need to read his story.
As Capuzzo himself says, “I don’t know of a bigger story in the world.”
On December 8 2020, FLCCC member Dr Pierre Kory gave nine minutes of impassioned testimony to the US Homeland Security Committee Meeting on the potent anti-viral, anti-inflammatory benefits of ivermectin. A total of 9 million people (myself included) saw the video on YouTube before it was taken down by YouTube’s owner, Google. As Capuzzo exhaustively lays out, both traditional and social media have gone to extraordinary lengths to keep people in the dark about ivermectin. So effective has this been that even in some of the countries that have benefited most from its use (such as Mexico and Argentina) many people are completely unaware of its existence. And this is no surprise given how little information is actually seeping out into the public arena.
A news blackout by the world’s leading media came down on Ivermectin like an iron curtain. Reporters who trumpeted the COVID-19 terror in India and Brazil didn’t report that Ivermectin was crushing the P-1 variant in the Brazilian rain forest and killing COVID-19 and all variants in India. That Ivermectin was saving tens of thousands of lives in South America wasn’t news, but mocking the continent’s peasants for taking horse paste was. Journalists denied the world knowledge of the most effective life-saving therapies in the pandemic, Kory said, especially among the elderly, people of color, and the poor, while wringing their hands at the tragedy of their disparate rates of death.
Three days after Kory’s testimony, an Associated Press “fact-check reporter” interviewed Kory “for twenty minutes in which I recounted all of the existing trials evidence (over fifteen randomized and multiple observational trials) all showing dramatic benefits of Ivermectin,” he said. Then she wrote: “AP’S ASSESSMENT: False. There’s no evidence Ivermectin has been proven a safe or effective treatment against COVID-19.” Like many critics, she didn’t explore the Ivermectin data or evidence in any detail, but merely dismissed its “insufficient evidence,” quoting instead the lack of a recommendation by the NIH or WHO. To describe the real evidence in any detail would put the AP and public health agencies in the difficult position of explaining how the lives of thousands of poor people in developing countries don’t count in these matters.
Not just in media but in social media, Ivermectin has inspired a strange new form of Western and pharmaceutical imperialism. On January 12, 2021, the Brazilian Ministry of Health tweeted to its 1.2 million followers not to wait with COVID-19 until it’s too late but “go to a Health Unit and request early treatment,” only to have Twitter take down the official public health pronouncement of the sovereign fifth largest nation in the world for “spreading misleading and potentially harmful information.” (Early treatment is code for Ivermectin.) On January 31, the Slovak Ministry of Health announced its decision on Facebook to allow use of Ivermectin, causing Facebook to take down that post and removed the entire page it was on, the Ivermectin for MDs Team, with 10,200 members from more than 100 countries.
In Argentina, Professor and doctor Hector Carvallo, whose prophylactic studies are renowned by other researchers, says all his scientific documentation for Ivermectin is quickly scrubbed from the Internet. “I am afraid,” he wrote to Marik and his colleagues, “we have affected the most sensitive organ on humans: the wallet…” As Kory’s testimony was climbing toward nine million views, YouTube, owned by Google, erased his official Senate testimony, saying it endangered the community. Kory’s biggest voice was silenced.
Continue reading “Ivermectin, media outlets “debunk” as an effective antiviral”
From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.Led by the University of Oxford, PRINCIPLE is investigating treatments for people at more risk of serious illness from COVID-19 which can speed up recovery, reduce the severity of symptoms and prevent the need for hospital admission. The study has so far recruited more than 5,000 volunteers from across the UK.
Ivermectin is a safe, broad spectrum antiparasitic drug which is in wide use globally to treat parasitic infections.
With known antiviral properties, ivermectin has been shown to reduce SARS-CoV-2 replication in laboratory studies. Small pilot studies show that early administration with ivermectin can reduce viral load and the duration of symptoms in some patients with mild COVID-19. Even though ivermectin is used routinely in some countries to treat COVID-19, there is little evidence from large-scale randomised controlled trials to demonstrate that it can speed up recovery from the illness or reduce hospital admission. Professor Chris Butler, from the University Oxford’s Nuffield Department of Primary Care Health Sciences, Joint Chief Investigator of the PRINCIPLE trial, said, ‘Ivermectin is readily available globally, has been in wide use for many other infectious conditions so it’s a well-known medicine with a good safety profile, and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries. By including ivermectin in a large-scale trial like PRINCIPLE, we hope to generate robust evidence to determine how effective the treatment is against COVID-19, and whether there are benefits or harms associated with its use.’ Following a screening questionnaire to confirm eligibility, participants enrolled in the study will be randomly assigned to receive a three-day course of ivermectin treatment. They will be followed-up for 28 days and will be compared with participants who have been assigned to receive the usual standard of NHS care only. People aged 18 to 64 with certain underlying health conditions or shortness of breath from COVID-19, or aged over 65, are eligible to join the trial within the first 14 days of experiencing COVID-19 symptoms or receiving a positive test. People with severe liver disease, who are on the blood-thinning medication warfarin, or taking other treatments known to interact with ivermectin, will be excluded.
https://youtu.be/YV2H6_0i4f0
According to a new study conducted at Sheba’s Center for Travel Medicine and Tropical Disease, one viable and readily available treatment option can be found in Ivermectin, a broad-spectrum antiparasitic agent, most commonly used in developing countries. The study, directed by Prof. Eli Schwartz, indicated that Ivermectin reduces the duration of COVID-19 infection.
According to Prof. Schwartz: “We decided to go for Ivermectin because we knew its safety profile well … I decided to test it on patients during the early stages of the disease, to see if it can act a bit like a vaccine and shorten or prevent the contagious stage, and thus break the transmission chain and shorten the isolation period … the study showed that Ivermectin really acted well and shortened the contagious period … The results are very encouraging, and indicate that the drug has antiviral effects.”
Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection.
Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3 days vs. placebo in non-hospitalized COVID-19 patients. RT-PCR from a nasopharyngeal swab was obtained at recruitment and then every two days. Primary endpoint was reduction of viral-load on the 6th day (third day after termination of treatment) as reflected by Ct level>30 (non-infectious level). The primary outcome was supported by determination of viral culture viability.
Results Eighty-nine patients were eligible (47 in ivermectin and 42 in placebo arm). Their median age was 35 years. Females accounted for 21·6%, and 16·8% were asymptomatic at recruitment. Median time from symptom onset was 4 days. There were no statistical differences in these parameters between the two groups.
On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo arm (OR 2·62; 95% CI: 1·09-6·31). In a multivariable logistic-regression model, the odds of a negative test at day 6 was 2.62 time higher in the ivermectin group (95% CI: 1·06–6·45). Cultures at days 2 to 6 were positive in 3/23 (13·0%) of ivermectin samples vs. 14/29 (48·2%) in the placebo group (p=0·008).
Conclusions There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.
The study is registered at ClinicalTrials.gov NCT 044297411.
PS Israel has started a even bigger clinical study.
https://youtu.be/5MNsM-ZhRS4
This video we will discuss and review a trial from ClinicalTrials.gov that have reported their results, but not published them. It is a randomized, double blinded, placebo control trial out of Bangladesh comparing treatment with Ivermectin and Doxycycline with standard care (tylenol, vitamin D, steroids as needed, oxygen as needed, etc) versus standard care alone. Their reported results were quite impressive. They reported increased clinical improvement at 7 days, decreased clinical deterioration at 30 days, and decreased viral loads at 14 days in those who received IVM and Doxy! Were there any adverse effects? Check out the video for all the details! Link to the study below:
https://youtu.be/V4fEBK1inj4
Link Here: https://doi.org/10.1016/j.chest.2020.10.009
Original in-vitro study about Ivermectin https://www.ncbi.nlm.nih.gov/pmc/arti…
A study from bangladesh found that Ivermectin + Doxyclyclin significantly reduces mortality and morbidity in COVID-19 patients. https://clinicaltrials.gov/ct2/show/s…
A systemic review of the antiviral activity of Ivermectin https://www.nature.com/articles/s4142… https://journal.chestnet.org/article/… PDF for the above study after it was accepted
https://journal.chestnet.org/article/… Pre-print of the above study https://www.medrxiv.org/content/10.11…
A search of various Ivermectin studies for your reading pleasure https://clinicaltrials.gov/ct2/result…
Iota carrageenan and Ivermectin oral drops https://clinicaltrials.gov/ct2/show/r…
Here is a index of the Clinical studies I have reviewed their are 44 of what i call suppressed studies. Think about it big Pharah has been given world wide 250 billion for the various vaccines. The medicines in the studies cost pennies a dose. Big Pharma wins the and over 2 million people dead have lost. they did not have to die:
https://clinicaltrials.gov/ct2/results?cond=Covid19&term=ivermectin&cntry&state&city&dist
https://youtu.be/Tq8SXOBy-4w
Pierre Kory, M.D., Associate Professor of Medicine at St. Luke’s Aurora Medical Center, delivers passionate testimony during the Senate Homeland Security and Governmental Affairs Committee hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II.”
Ivermectin tablets (Stromectol) is an approved medicine by the FDA for use in intestinal worms Strongyloides stercoralis and Onchocerca volvulus
As Ivermectin is already a FDA approved medicine we already know that it has been established as safe for human use.
Salvavida Suggestions:
In closing we make no medical claims whats so ever for the above. These are suggestions i found in Published research from what i regard as credible sources. In these news pages i Have published the studies that support these conclusion.
Before taking any medicines, home remedies, vitamins or a drink of water consult your medical professional.
I am taking this very very serious. I lost 3 more people this weekend. Its now killing people i know in their early sixties. But we all know i am FULL OF SHIT and a criminal rouge…..
Nick Bit: This guy is hard to understand. But a 30 minute video could save your life. You decide… Smart people live and stupid people die a horrible agonizing death. Grasping for air like a fish out of the water. By the way the dosage study he refers to is in Spanish and i have read it!
“To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d. The goal should be to raise 25(OH)D concentrations above 40–60 ng/mL (100–150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.”